DS
FSTX

David Shaw’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

David Shaw’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,865
Closed -$56K – 5967
2022
Q1 		$56K Buy
+15,865
New +$58.6K ﹤0.01% 5121

Other funds holding FSTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

David Shaw's FSTX Position: Q2 2022 in Review

David Shaw sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q2 2022, closing a stake of 15,865 shares — an estimated $56K sold.

David Shaw first reported a position in FSTX in Q1 2022 and held it in 1 quarter. The position peaked at $56K in Q1 2022. 53 funds tracked by Wall St. Rank hold FSTX as of Q2 2022.

  • David Shaw reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 15,865 F-star Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $56K.
  • David Shaw first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • David Shaw's F-star Therapeutics, Inc. Common Stock position peaked at $56K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.